Anandamide and 2-AG Did Not Rise Together in an Alcohol–Heart Experiment
A mouse alcohol experiment summarized in a review reported increased myocardial anandamide without the same increase in 2-AG. Referring to both simply as elevated endocannabinoids would obscure the actual finding.
The measurements included function and tissue chemistry
Kunos describes an acute ethanol model with reduced cardiac contractility assessed by pressure–volume measurements and echocardiography. Tissue anandamide increased, while 2-AG did not show the corresponding change.
The reviewed experiment also found attenuation or reversal of several responses after rimonabant, supporting investigation of CB1 involvement under those conditions.
A shared receptor system does not make ligands identical
Anandamide and 2-AG can participate in the same broad signaling system while differing in production, degradation and response to an exposure. A pooled label can hide a meaningful positive-versus-null distinction.
An intervention result adds mechanistic information, but should remain tied to the measured function, drug and experimental context.
The exposure was alcohol, not marijuana
These were mouse cardiovascular findings after ethanol, not human measurements after cannabis use. The presence of endocannabinoid signaling does not convert them into a cannabis-exposure study.
The review supports a specific research mechanism. It does not determine an individual person’s cardiac risk, establish an emergency treatment or justify a clinical inference from a cannabinoid result alone.
Related: Interpreting cannabis tolerance claims.
Research cited
Kunos G Alcoholism, clinical and experimental research · 2020 · 44(4):790 PMID 32056226 · DOI 10.1111/acer.14306. Interactions Between Alcohol and the Endocannabinoid System..
